SLN (Silence Therapeutics) Tariff Resilience Score: 8/10 (As of Jun. 29, 2026)


SLN Silence Therapeutics PLC SLN
45 GF Score
Price $10.09
GF Value $0.23
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Tariff Resilience Score?

Silence Therapeutics SLN +0.25% 45 Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus rates SLN with a GF Score™ of 45/100 and a GF Value™ of $0.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,375 Biotechnology companies, Silence Therapeutics ranks better than 98.69% on this metric.

Silence Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Silence Therapeutics has Biotech industry with minimal direct tariff exposure. Manufacturing and R&D are primarily domestic, with international sales. Historical tariffs have had negligible impact. Strong pricing power and industry-specific exemptions enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Silence Therapeutics might have Highly Resilient.

Silence Therapeutics  (NAS:SLN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Silence Therapeutics Tariff Resilience Score Related Terms

SLN vs IMRX, VRXA, MGNX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Silence Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Tariff Resilience Score falls into.


SLN
45GF Score
Silence Therapeutics PLC SLN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Silence Therapeutics (SLN) has a Tariff Resilience Score of 8 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Silence Therapeutics ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Silence Therapeutics' Tariff Resilience Score too high?
Silence Therapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Silence Therapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, Silence Therapeutics ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Silence Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Tariff Resilience Score compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #18 out of 1375 companies for Tariff Resilience Score. This places Silence Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Silence Therapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silence Therapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.23, compared to a current price of $10.09 — trading 4287% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Silence Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $10.09 is trading 4287% above its estimated GF Value™ of $0.23. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Tariff Resilience Score: 8
  • GF Value™: $0.23 vs. price of $10.09 (4287% above fair value)
  • GF Score™: 45/100 with 5 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1375)

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
45GF Score

Get the complete analysis for SLN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.09
Price
$0.23
GF Value